Cited by 716Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsClinical Laboratory Practices and Quality Control

Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic

Open access
Hampel, Harald, O’Bryant, Sid E., Molinuevo, José L., Zetterberg, Henrik, Masters, Colin L., Lista, Simone, Kiddle, Steven J., Batrla, Richard +1 more·2018·Nature Reviews Neurology

Abstract

Biomarker discovery and development for clinical research, diagnostics and therapy monitoring in clinical trials have advanced rapidly in key areas of medicine, notably oncology and cardiovascular diseases, allowing for rapid early detection and supporting the evolution of biomarker-guided precision medicine-based targeted therapies. In Alzheimer’s disease (AD), breakthroughs in biomarker identification and validation include the cerebrospinal fluid (CSF) and positron emission tomography (PET) markers of amyloid β (Aβ) and tau proteins, which are highly accurate in detecting the presence of pathophysiological and neuropathological changes of AD. However, their high cost, insufficient accessibility, or invasiveness may limit their use as viable first-line tools for detecting patterns of pathophysiology. Therefore, a multi-stage, tiered approach is needed, prioritizing development of an initial screen to exclude from these tests the high numbers of people with cognitive deficits who do not demonstrate evidence of underlying AD pathophysiology. This perspective summarizes the efforts of a working group that aimed to survey the current landscape of blood-based AD biomarkers, and outlines operational steps for an effective academic-industry co-development and path forward from identification and assay development to validation for clinical use.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41582-018-0079-7

Cites

133 of 133 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several studies have demonstrated that plasma Aβ40, Aβ42, P-tau and NfL are to some extent correlated with PET scan and CSF detection results.

    “Several studies have demonstrated that plasma Aβ40, Aβ42, phosphorylated tau (P-tau) and neurofilament light (NfL) are to some extent correlated with PET scan and CSF detection results6–8.”

    From Integrated algorithm combining plasma biomarkers and cognitive assessments accurately predicts brain β-amyloid pathology (2023) · cites this paper as [6]

    The Introduction’s “Current landscape” section (page unavailable) reports weak but significant plasma–CSF correlations for Aβ40 and Aβ42, an association between plasma amyloid measures and amyloid PET results, and a strong serum–CSF correlation for NfL. It discusses plasma tau and later PET-measured hypometabolism, but does not establish the claimed PET or CSF correlations for phosphorylated tau specifically. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • MRI and PET are highly accurate in detecting pathophysiological and neuropathological changes of AD and are used in drug development.

    “Currently, techniques like structural magnetic resonance imaging (MRI), and molecular imaging of deposited Aβ and tau proteins using positron emission tomography (PET), are highly accurate in detecting the presence of pathophysiological and neuropathological changes of AD and are used in the drug development [10, 11].”

    From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [11]

    The Introduction (‘Why are blood-based biomarkers needed for AD?’; page unavailable) says PET can improve diagnostic accuracy, and the Conclusions describe PET as a confirmatory diagnostic modality. The paper does not establish that structural MRI is highly accurate for detecting the specified AD changes or that MRI and PET are used in drug development. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [118]Nistico G Broich K Hampel H Need for new guidelines for Alzheimer's disease clinical trials European Journal of Neurodegenerative Diseases 2013 2 181 186

Cited by

Sorted by citations

Authors
Hampel, H., O’Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., Kiddle, S. J., Batrla, R., & Blennow, K.
Affiliations
  • Inserm (FR)
  • University of North Texas Health Science Center (US)
  • Pasqual Maragall Foundation (ES)
  • Sahlgrenska University Hospital (SE)
  • The University of Melbourne (AU)
  • King's College London (GB)
  • Roche Diagnostics International AG (Switzerland) (CH)
Corresponding author
  • Hampel, Harald
  • Blennow, Kaj
Venue
Nature Reviews Neurology
Published
2018-10-08
Volume
14
Issue
11
Pages
639-652
ISSN
  • 1759-4758 (ISSN-L)
  • 1759-4766
OpenAlex
W2895381107
Cited by
716
References
133
Citations by year
2026: 89 · 2025: 91 · 2024: 95 · 2023: 91 · 2022: 104 · 2021: 102 · 2020: 91 · 2019: 50 · 2018: 2 · 2015: 1
FWCI
9.46
Type
journal article
Language
en
Open access
Locations
  • Nature Reviews Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • HAL (submittedVersion, other-oa)
  • UCL Discovery (University College London) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion)
  • Apollo (University of Cambridge) (submittedVersion)
  • Apollo
Funders
  • Agence Nationale de la Recherche (ANR-10-IAHU-0006)
  • Medical Research Council (MR/P021573/1, MR/L011859/1)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Physiology › Clinical Laboratory Practices and Quality Control
Keywords
Alzheimer's disease, blood-based biomarkers, liquid biopsy, amyloid-beta, tau protein, cerebrospinal fluid biomarkers, positron emission tomography, biomarker validation, clinical translation, university-industry collaboration, early detection, targeted therapy monitoring
MeSH terms
Alzheimer Disease, Humans, Biomarkers, Early Diagnosis, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review